Outcomes of antiretroviral therapy in children in Asia and Africa

A comparative analysis of the IeDEA pediatric multiregional collaboration

Valeriane Leroy, Karen Malateste, Helena Rabie, Pagakrong Lumbiganon, Samuel Ayaya, Fatoumata Dicko, Mary Ann Davies, Azar Kariminia, Kara Wools-Kaloustian, Edmond Aka, Samuel Phiri, Linda Aurpibul, Constantin Yiannoutsos, Haby Signaté-Sy, Lynne Mofenson, François Dabis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.

Original languageEnglish
Pages (from-to)208-219
Number of pages12
JournalJournal of Acquired Immune Deficiency Syndromes
Volume62
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Western Africa
Eastern Africa
Southern Africa
Pediatrics
HIV
Therapeutics
Investigational Therapies
Reverse Transcriptase Inhibitors
Private Sector
Public Sector
Workload
Polymerase Chain Reaction
Survival
Incidence
Pharmaceutical Preparations

Keywords

  • Africa
  • antiretroviral therapy
  • Asia
  • children
  • cohort studies
  • HIV infection
  • loss to follow-up
  • low-income countries
  • mortality

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Outcomes of antiretroviral therapy in children in Asia and Africa : A comparative analysis of the IeDEA pediatric multiregional collaboration. / Leroy, Valeriane; Malateste, Karen; Rabie, Helena; Lumbiganon, Pagakrong; Ayaya, Samuel; Dicko, Fatoumata; Davies, Mary Ann; Kariminia, Azar; Wools-Kaloustian, Kara; Aka, Edmond; Phiri, Samuel; Aurpibul, Linda; Yiannoutsos, Constantin; Signaté-Sy, Haby; Mofenson, Lynne; Dabis, François.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 62, No. 2, 01.02.2013, p. 208-219.

Research output: Contribution to journalArticle

Leroy, V, Malateste, K, Rabie, H, Lumbiganon, P, Ayaya, S, Dicko, F, Davies, MA, Kariminia, A, Wools-Kaloustian, K, Aka, E, Phiri, S, Aurpibul, L, Yiannoutsos, C, Signaté-Sy, H, Mofenson, L & Dabis, F 2013, 'Outcomes of antiretroviral therapy in children in Asia and Africa: A comparative analysis of the IeDEA pediatric multiregional collaboration', Journal of Acquired Immune Deficiency Syndromes, vol. 62, no. 2, pp. 208-219. https://doi.org/10.1097/QAI.0b013e31827b70bf
Leroy, Valeriane ; Malateste, Karen ; Rabie, Helena ; Lumbiganon, Pagakrong ; Ayaya, Samuel ; Dicko, Fatoumata ; Davies, Mary Ann ; Kariminia, Azar ; Wools-Kaloustian, Kara ; Aka, Edmond ; Phiri, Samuel ; Aurpibul, Linda ; Yiannoutsos, Constantin ; Signaté-Sy, Haby ; Mofenson, Lynne ; Dabis, François. / Outcomes of antiretroviral therapy in children in Asia and Africa : A comparative analysis of the IeDEA pediatric multiregional collaboration. In: Journal of Acquired Immune Deficiency Syndromes. 2013 ; Vol. 62, No. 2. pp. 208-219.
@article{4c7d55cfae50443eb7b77d133579e8ed,
title = "Outcomes of antiretroviral therapy in children in Asia and Africa: A comparative analysis of the IeDEA pediatric multiregional collaboration",
abstract = "BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3{\%} in East Africa, 5.4{\%} in Asia, 5.7{\%} in Southern Africa, and 7.4{\%} in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10{\%}, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1{\%} in Asia, 9.0{\%} in Southern Africa, 14.0{\%} in East Africa, and 21.8{\%} in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.",
keywords = "Africa, antiretroviral therapy, Asia, children, cohort studies, HIV infection, loss to follow-up, low-income countries, mortality",
author = "Valeriane Leroy and Karen Malateste and Helena Rabie and Pagakrong Lumbiganon and Samuel Ayaya and Fatoumata Dicko and Davies, {Mary Ann} and Azar Kariminia and Kara Wools-Kaloustian and Edmond Aka and Samuel Phiri and Linda Aurpibul and Constantin Yiannoutsos and Haby Signat{\'e}-Sy and Lynne Mofenson and Fran{\cc}ois Dabis",
year = "2013",
month = "2",
day = "1",
doi = "10.1097/QAI.0b013e31827b70bf",
language = "English",
volume = "62",
pages = "208--219",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Outcomes of antiretroviral therapy in children in Asia and Africa

T2 - A comparative analysis of the IeDEA pediatric multiregional collaboration

AU - Leroy, Valeriane

AU - Malateste, Karen

AU - Rabie, Helena

AU - Lumbiganon, Pagakrong

AU - Ayaya, Samuel

AU - Dicko, Fatoumata

AU - Davies, Mary Ann

AU - Kariminia, Azar

AU - Wools-Kaloustian, Kara

AU - Aka, Edmond

AU - Phiri, Samuel

AU - Aurpibul, Linda

AU - Yiannoutsos, Constantin

AU - Signaté-Sy, Haby

AU - Mofenson, Lynne

AU - Dabis, François

PY - 2013/2/1

Y1 - 2013/2/1

N2 - BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.

AB - BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.

KW - Africa

KW - antiretroviral therapy

KW - Asia

KW - children

KW - cohort studies

KW - HIV infection

KW - loss to follow-up

KW - low-income countries

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=84872874429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872874429&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31827b70bf

DO - 10.1097/QAI.0b013e31827b70bf

M3 - Article

VL - 62

SP - 208

EP - 219

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -